RBD5044

Ribocure Pharmaceuticals AB · Phase 2 active Small molecule

At a glance

Generic name	RBD5044
Sponsor	Ribocure Pharmaceuticals AB
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia (PHASE2)
A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RBD5044 CI brief — competitive landscape report
RBD5044 updates RSS · CI watch RSS
Ribocure Pharmaceuticals AB portfolio CI